GlobeNewswire by notified

Novotech Publishes Report on Research into Endometrial Cancer, a Leading Cause of Gynecology Malignancy Mortality


BOSTON, June 20, 2024 (GLOBE NEWSWIRE) -- Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has released a comprehensive research report - Endometrial cancer - Global Clinical Trial Landscape.

The report provides insights and key data on the global landscape of clinical trials for uterine cancer, primarily endometrial cancer (EC), focusing on prevalence, funding landscape, emerging trends, therapies, trial density, and patient recruitment for trial planning and research.

Since 2018, over 1,200 EC clinical trials have been initiated worldwide, with North America and Asia-Pacific contributing 39% and 33% of trials, respectively, followed by Europe at 22%.

EC ranks as the second most common, and fourth leading, cause of death globally among gynecology malignancies. In 2022 alone, there were nearly 420,370 new cases of EC globally, with approximately 97,720 deaths. 

  • Asia (167,430) accounts for nearly 40% of global cases of EC in 2022
  • Europe (124,874) 
  • North America (73,977)

Within Asia:

  • Mainland China reported the highest incidence with 77,722 cases
  • The United States had the second-highest incidence globally with 66,055 cases, accompanied by the highest ASR of 22.5 per 100,000 population
  • In Europe, Russia reported the third-highest incidence with 29,852 cases

Currently, the standard of care for EC is surgery with either partial or total hysterectomy and bilateral salpingo-oophorectomy (TH/BSO). For recurrent EC patients, treatments vary based on extent and prior success, including surgery, radiation, and systemic therapy such as chemotherapy and hormonal therapy. 

The report notes that projections for EC show an increase in new cases over the next 25 years, potentially surpassing 600,000 annual new cases by 2044.

This demand for therapies has seen EC clinical trial activity increase globally from 2014 to 2023, with the Asia-Pacific region experiencing the highest increase with a Compound Annual Growth Rate (CAGR) of 22.9%. ROW followed closely at 14.9%, and the North American and European regions showed a steady growth rate at 9.7% and 5.2% respectively.

Similarly, the funding landscape is strong with the United States dominating in venture capital funding for EC research between 2019 and 2023, followed by China, with investments totalling $2129 million and $894 million, respectively. Public funding initiatives in Australia and the United States focused on expanding and improving the quality of care. 

Further key clinical trial trend and treatment developments from the report include: 

  • The United States led trial activity in North America, while Mainland China led in the Asia-Pacific region, followed by Australia and South Korea.
  • The trial phase trends show North America and Asia-Pacific conducting a higher volume of early and mid-phase trials (Phase 1 and 2), while Europe and the ROW concentrate on later-stage trials (Phase 3).
  • Asia-Pacific demonstrates the shortest median enrollment period (15.1 months) and the highest median recruitment rate (1.1 subjects per site per month), indicating efficient patient recruitment.
  • There are approximately six drugs in preclinical stages, 15 in Phase I trials, and 12 in combined Phase I/II studies.
  • In Phase III trials, Programmed Cell Death 1 Ligand 1 Inhibitor dominates the mechanism of action (MOA), followed by Programmed Cell Death Protein 1 Antagonist and Poly [ADP Ribose] Polymerase 1 Inhibitor.
  • Marketed drugs for EC mainly target DNA synthesis inhibitors, progesterone receptor agonists, and tubulin inhibitors.

The Novotech research analyst team provides these expert reports every month, completely free of charge. In addition to the highlights above, the report provides an in-depth SWOT analysis, to guide biotech firms on strategic decision-making, research opportunities, and challenges. They tackle the potential and real hurdles biotech firms face in specific therapeutic areas in the hopes of positively impacting and informing clinical trial decision-making, eventually improving success rates with new treatments.  

Download the report here 

About Novotech
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.

Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.

The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.

For more information or to speak to an expert team member visit

A photo accompanying this announcement is available at

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support investments in research, development and innovation11.6.2024 12:00:00 CEST | Press release

Turin, 11th June 2024. Iveco Group N.V. (EXM: IVG), a global automotive leader active in the Commercial & Specialty Vehicles, Powertrain and related Financial Services arenas, has successfully signed a term loan facility of 150 million euros with Cassa Depositi e Prestiti (CDP), for the creation of new projects in Italy dedicated to research, development and innovation. In detail, through the resources made available by CDP, Iveco Group will develop innovative technologies and architectures in the field of electric propulsion and further develop solutions for autonomous driving, digitalisation and vehicle connectivity aimed at increasing efficiency, safety, driving comfort and productivity. The financed investments, which will have a 5-year amortising profile, will be made by Iveco Group in Italy by the end of 2025. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a

DSV, 1115 - SHARE BUYBACK IN DSV A/S11.6.2024 11:22:17 CEST | Press release

Company Announcement No. 1115 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-25478,1001,023.01489,100,86026:3 June 20247,0001,050.597,354,13027:4 June 20245,0001,055.705,278,50028:6 June20243,0001,096.273,288,81029:7 June 20244,0001,106.174,424,68

Landsbankinn hf.: Offering of covered bonds11.6.2024 11:16:36 CEST | Press release

Landsbankinn will offer covered bonds for sale via auction held on Thursday 13 June at 15:00. An inflation-linked series, LBANK CBI 30, will be offered for sale. In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CBI 24 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99,594. Expected settlement date is 20 June 2024. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email

Relay42 unlocks customer intelligence with a new insights and reporting module, powered by Amazon QuickSight11.6.2024 11:00:00 CEST | Press release

AMSTERDAM, June 11, 2024 (GLOBE NEWSWIRE) -- Relay42, a leading European Customer Data Platform (CDP), is leveraging Amazon QuickSight to power its new real-time customer intelligence, reporting, and dashboard module. Harnessing the breadth and quality of customer data, the new Insights module empowers marketing teams to dive deep into customer behaviors and gain invaluable insights into the performance of their marketing programs across all online, offline, paid, and owned marketing channels. Preview of the Relay42 Insights module, in pre-beta version Key capabilities of the Relay42 Insights module include: Deep insights into customer behaviors: With the Relay42 Insights module, marketers can ask unlimited questions about their data and gain a deeper understanding of how to serve their customers more effectively. Simplicity with AI-powered querying: Marketers can use artificial intelligence to query their data using natural language search, reducing the reliance on data scientists. Us

Metasphere Labs Announces X Spaces Event on the Topic of Green Bitcoin Mining and Sound Money for Sustainability11.6.2024 10:30:00 CEST | Press release

VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere Labs" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce an engaging Twitter Spaces event on Green Bitcoin mining, energy markets, and sustainability on July 3, 2024 at 2 p.m. ET. Follow us on X at MetasphereLabs for updates and to join the event. What We'll Discuss Bitcoin Mining Basics: Understand the fundamentals of Bitcoin mining.Energy Market Dynamics: Explore how Bitcoin mining interacts with energy markets.Sustainable Innovations: Learn about our efforts to promote sustainability in Bitcoin mining.Sound Money: Discover how tamper-proof currency can enhance stability.Efficient Payment Rails: See how fast, neutral payment systems support humanitarian projects.Carbon Footprint: Compare Bitcoin's environmental impact with traditional banking. "We're excited to host this event and dive into the critical topics of Bitcoin

HiddenA line styled icon from Orion Icon Library.Eye